Episode 7: Quantitative EEG – Effects of CT1812 on Measures of Synaptic Function in Alzheimer’s Disease

Featuring:
Anthony Caggiano, M.D., Ph.D. (moderator)
Cognition Therapeutics
Chief Medical Officer
Willem de Haan, M.D., Ph.D.
Alzheimer Center at Amsterdam University Medical Center
Neurologist and Senior Researcher
Philip Scheltens, M.D.
EQT Life Sciences
Partner and Head of Dementia Fund
Former Director of the Alzheimer Center at Amsterdam University Medical Center
Index:
0:00 Introduction
0:44 Rationale for the SEQUEL Study Design
2:10 EEG in neurodegenerative diseases
4:33 Findings from SEQUEL
9:52 Key Takeaways

share this video

Scroll to Top

Thank you for your interest in Cognition’s publications. A PDF of the poster you are interested in will be made available in accordance with the congress’ embargo policy. Please check back soon. 

You are now leaving the Cognition Therapeutics website

Cognition Therapeutics assumes no responsibility for the content of third-party website. Neither does Cognition control, endorse or guarantee any aspect of your use of third-party sites. We encourage you to read and evaluate terms of use, privacy and other policies of the destination site as they may differ from Cognition’s policies.

You are now leaving the Cognition Therapeutics website

Cognition Therapeutics assumes no responsibility for the content of third-party website. Neither does Cognition control, endorse or guarantee any aspect of your use of third-party sites. We encourage you to read and evaluate terms of use, privacy and other policies of the destination site as they may differ from Cognition’s policies.

You are now leaving the Cognition Therapeutics website

Cognition Therapeutics assumes no responsibility for the content of third-party website. Neither does Cognition control, endorse or guarantee any aspect of your use of third-party sites. We encourage you to read and evaluate terms of use, privacy and other policies of the destination site as they may differ from Cognition’s policies.

You are now leaving the Cognition Therapeutics website

Cognition Therapeutics assumes no responsibility for the content of third-party website. Neither does Cognition control, endorse or guarantee any aspect of your use of third-party sites. We encourage you to read and evaluate terms of use, privacy and other policies of the destination site as they may differ from Cognition’s policies.

You are now leaving the Cognition Therapeutics website

Cognition Therapeutics assumes no responsibility for the content of third-party website. Neither does Cognition control, endorse or guarantee any aspect of your use of third-party sites. We encourage you to read and evaluate terms of use, privacy and other policies of the destination site as they may differ from Cognition’s policies.